ERAXIS Drug Patent Profile
✉ Email this page to a colleague
When do Eraxis patents expire, and when can generic versions of Eraxis launch?
Eraxis is a drug marketed by Vicuron Holdings and is included in one NDA.
The generic ingredient in ERAXIS is anidulafungin. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the anidulafungin profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ERAXIS?
- What are the global sales for ERAXIS?
- What is Average Wholesale Price for ERAXIS?
Summary for ERAXIS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 53 |
| Clinical Trials: | 11 |
| Patent Applications: | 4,178 |
| Drug Prices: | Drug price information for ERAXIS |
| What excipients (inactive ingredients) are in ERAXIS? | ERAXIS excipients list |
| DailyMed Link: | ERAXIS at DailyMed |
Recent Clinical Trials for ERAXIS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Center for Research Resources (NCRR) | Phase 4 |
| Texas Tech University Health Sciences Center | Phase 4 |
| University of Texas Southwestern Medical Center | Phase 4 |
Pharmacology for ERAXIS
| Drug Class | Echinocandin Antifungal |
US Patents and Regulatory Information for ERAXIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-002 | Nov 14, 2006 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ERAXIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | ⤷ Start Trial | ⤷ Start Trial |
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-002 | Nov 14, 2006 | ⤷ Start Trial | ⤷ Start Trial |
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-002 | Nov 14, 2006 | ⤷ Start Trial | ⤷ Start Trial |
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-002 | Nov 14, 2006 | ⤷ Start Trial | ⤷ Start Trial |
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | ⤷ Start Trial | ⤷ Start Trial |
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for ERAXIS
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Pfizer Europe MA EEIG | Ecalta | anidulafungin | EMEA/H/C/000788Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years. | Authorised | no | no | no | 2007-09-20 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ERAXIS
See the table below for patents covering ERAXIS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 217635 | ⤷ Start Trial | |
| Australia | 3534193 | ⤷ Start Trial | |
| Australia | 6552996 | ⤷ Start Trial | |
| Australia | 689391 | ⤷ Start Trial | |
| Brazil | 1100417 | ⤷ Start Trial | |
| Brazil | 9301232 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ERAXIS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0561639 | 91406 | Luxembourg | ⤷ Start Trial | 91406, EXPIRES: 20180318 |
| 0561639 | CA 2008 00017 | Denmark | ⤷ Start Trial | |
| 0561639 | 300334 | Netherlands | ⤷ Start Trial | 300334, 20130318, EXPIRES: 20180317 |
| 0561639 | SPC002/2008 | Ireland | ⤷ Start Trial | SPC002/2008: 20081105, EXPIRES: 20180317 |
| 0561639 | 08C0009 | France | ⤷ Start Trial | PRODUCT NAME: ANIDULAFUNGINE; REGISTRATION NO/DATE: EU/1/07/416/001 20070920 |
| 0561639 | SPC/GB08/016 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: ANIDULAFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/416/001 20070920 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch